본문으로 건너뛰기
← 뒤로

Matrix-integrated microfluidic tumor models for evaluating drug delivery systems and pre-clinical testing.

3/5 보강
Advanced drug delivery reviews 📖 저널 OA 20% 2025: 1/8 OA 2026: 5/22 OA 2025~2026 2026 Vol.232() p. 115836 cited 1 OA 3D Printing in Biomedical Research
TL;DR This review highlights emerging computational and data-driven approaches, together with current translational and regulatory perspectives, that position matrix-integrated tumor-on-chip technologies as powerful preclinical tools that aim to bridge the gap between simplified in vitro assays and more complex in vivo studies.
Retraction 확인
출처
PubMed DOI OpenAlex Semantic 마지막 보강 2026-04-29
OpenAlex 토픽 · 3D Printing in Biomedical Research Cancer Cells and Metastasis Nanoparticle-Based Drug Delivery

Guerrero-López P, Alamán-Díez P, Hernández-Hatibi S, Balsas P, García-Aznar JM

📖 무료 전문 🔓 OA PDF oa
📝 환자 설명용 한 줄

This review highlights emerging computational and data-driven approaches, together with current translational and regulatory perspectives, that position matrix-integrated tumor-on-chip technologies as

이 논문을 인용하기

↓ .bib ↓ .ris
APA Paula Guerrero-López, Pilar Alamán-Díez, et al. (2026). Matrix-integrated microfluidic tumor models for evaluating drug delivery systems and pre-clinical testing.. Advanced drug delivery reviews, 232, 115836. https://doi.org/10.1016/j.addr.2026.115836
MLA Paula Guerrero-López, et al.. "Matrix-integrated microfluidic tumor models for evaluating drug delivery systems and pre-clinical testing.." Advanced drug delivery reviews, vol. 232, 2026, pp. 115836.
PMID 41724330 ↗

Abstract

Drug delivery research strongly depends on experimental models that faithfully mimic the tumor microenvironment (TME) and its barriers to evaluate therapeutic efficacy. Conventional systems provide valuable insights but suffer from some limitations in physiological relevance, reproducibility, scalability or translational predictability. In this context, microfluidic 'tumor-on-chip' platforms have emerged as innovative tools that integrate engineering technology to model biological complexity, offering controlled microenvironments to investigate drug penetration, transport dynamics, and therapeutic response. A distinctive aspect of these microsystems is the possibility of incorporating matrices that mimic the extracellular matrix (ECM) of different tissues. These matrices enhance the ability of the in vitro models to replicate the structural, biochemical, and mechanical features of solid tumors. In this review, we focus on the application of microfluidic matrix-integrated tumor-on-chip platforms for drug delivery evaluation. We first outline key microenvironmental features that regulate therapeutic efficacy and discuss how they can be engineered within microfluidic models. We then examine how transport dynamics and delivery mechanisms are modeled under physiologically relevant conditions and review the use of these platforms to assess a broad range of therapeutic strategies, including nanocarriers, biologics, and gene- and cell-based therapies. Finally, we highlight emerging computational and data-driven approaches, together with current translational and regulatory perspectives, that position matrix-integrated tumor-on-chip technologies as powerful preclinical tools. These models aim to bridge the gap between simplified in vitro assays and more complex in vivo studies, ultimately accelerating the translation of drug delivery systems into clinical practice and paving the way for more personalized therapeutic strategies.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

같은 제1저자의 인용 많은 논문 (1)

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🔓 OA PDF 열기